Acadia Pharmaceuticals (NASDAQ: ACAD), a company developing novel treatments for disorders ... triggering a mass exodus among shareholders. Acadia's stock has shed more than a third of its value since Nuplazid's approval by the …
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) traded down about 27% Monday to post a new 52-week low of $15.74 after closing Friday at $21.53. The stock’s 52-week high is $41.20. Volume was more 10 times the daily average of around 2 …
Shares of major biotech companies stumbled Friday on concerns the sector may be overheated. The iShares NASDAQ …
A 1-for-20 reverse stock split was implemented on January 26, 2018. Clinical Trials & Near-term Catalysts: The lead drug candidate is M207 for the treatment of migraine. A long-term safety study of M207 is underway. -- The Company …
CHICAGO, April 9, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, DB, GM, NVS, …
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no …
Investor confidence in a potential acquisition of Acadia Pharmaceuticals (NASDAQ: ACAD) seems to have waned, and …
All four are rated Buy at Merrill Lynch. This stock got tagged recently, offering investors a very solid entry point. ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company based in San Diego and focused on the …